VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin

Cancer Letters

Volumn 373, Issue 1, 2016, Pages 1-11

  Luo, Minna ^a   Hou, Lei ^b   Li, Jian ^b   Shao, Shan ^a   Huang, Shangke ^a   Meng, Du ^a   Liu, Lifeng ^a   Feng, Lu ^a   Xia, Peng ^a   Qin, Tianjie ^a   Zhao, Xinhan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Breast cancer; Epithelial mesenchymal transition; NRP 1; Tumor progression; VEGF

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROPILIN 1; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN; CTNNB1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER CELL DESTRUCTION; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; AUTOCRINE EFFECT; BREAST TUMOR; CELL MOTION; DISEASE COURSE; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TIME FACTOR; TUMOR INVASION; TUMOR VOLUME;

ADULT; AGED; ANIMALS; APOPTOSIS; AUTOCRINE COMMUNICATION; BETA CATENIN; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MCF-7 CELLS; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUROPILIN-1; NF-KAPPA B; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84958056552     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.01.010     Document Type: Article

References (39)

1. Leung D.W., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246(4935):1306-1309.
2. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med 2011, 17(11):1359-1370.
3. Saharinen P., et al. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med 2014, 17(7):347-362.
4. Van Meter M.E., Kim E.S. Bevacizumab: current updates in treatment. Curr. Opin. Oncol 2010, 22(6):586-591.
5. Miller K., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med 2007, 357(26):2666-2676.
6. Hamerlik P., et al. Autocrine VEGF-VEGFR2-Neuropilin-signaling promotes glioma stem-like cell viability and tumor growth. J. Exp. Med 2012, 209(3):507-520.
7. Parikh A.A., et al. Neuropilin-in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am. J. Pathol 2004, 164(6):2139-2151.
8. Bielenberg D.R., et al. Neuropilins in neoplasms: expression, regulation, and function. Exp. Cell Res 2006, 312(5):584-593.
9. Beck B., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478(7369):399-403.
10. Lichtenberger B.M., et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010, 140(2):268-279.
11. Cao Y., et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res 2012, 72(16):3912-3918.
12. Pàez-Ribes M., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231.
13. Gonzalez-Moreno O., et al. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp. Cell Res 2010, 316(4):554-567.
14. Bachelder R.E., et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61(15):5736-5740.
15. Soker S., et al. Neuropilin-is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92(6):735-745.
16. Bagri A., Tessier-Lavigne M., Watts R.J. Neuropilins in tumor biology. Clin. Cancer Res 2009, 15(6):1860-1864.
17. Katoh M., Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol. Ther 2006, 5(9):1059-1064.
18. Huber M.A., et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest 2004, 114(4):569-581.
19. Napoleone F. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol 2002, 29(6, Suppl. 16):10-14.
20. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8(8):579-591.
21. Hong T., et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin. Cancer Res 2007, 13(16):4759-4768.
22. Raimondi C., Ruhrberg C. Neuropilin signalling in vessels, neurons and tumours. Semin. Cell Dev. Biol. Semaphor. Taste Percept 2013, 24(3):172-178.
23. Prud'Homme G.J., Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 2012, 3(9):921.
24. Goel H.L., Mercurio A.M. VEGF targets the tumour cell. Nat. Rev. Cancer 2013, 13(12):871-882.
25. Djordjevic S., Driscoll P.C. Targeting VEGF signalling via the neuropilin co-receptor. Drug Discov. Today 2013, 18(9-10):447-455.
26. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4(7):540-550.
27. Thiery J.P., et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890.
28. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29(34):4741-4751.
29. Paul Mak I.L.B.P. ERb impedes prostate cancer EMT by destabilizing HIF-1a and inhibiting VEGF-mediated snail nuclear localization: implications for gleason grading. Cancer Cell 2010, 10.1016/j.ccr.2010.02.030.
30. Lu K.V., et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22(1):21-35.
31. Yang A.D., et al. Vascular endothelial growth factor receptor-activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006, 66(1):46-51.
32. Yanagawa J., et al. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin. Cancer Res 2009, 15(22):6820-6829.
33. Feurino L.W., et al. IL-stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-expression in pancreatic cancer cells. Cancer Biol. Ther 2007, 6(7):1096-1100.
34. Matsushita A., Gotze T., Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res 2007, 67(21):10309-10316.
35. Hoesel B., Schmid J.A. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 2013, 12(86):1-15.
36. D'Amico M., et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3β and cAMP-responsive element-binding protein-dependent pathways. J. Biol. Chem 2000, 275(42):32649-32657.
37. Takahashi-Yanaga F., Sasaguri T. GSK-3β regulates cyclin D1 expression: a new target for chemotherapy. Cell. Signal 2008, 20(4):581-589.
38. Schmalhofer O., Brabletz S., Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28(1-2):151-166.
39. Gottardi C.J., Gumbiner B.M. Distinct molecular forms of β-catenin are targeted to adhesive or transcriptional complexes. J. Cell Biol 2004, 167(2):339-349.